Compare Abeona Therapeutics Inc (ABEO) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Xpeng Inc - ADR — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Xpeng Inc - ADR trades at $13.18 (market cap $12.75B). The key difference: Xpeng Inc - ADR is far larger — about 34.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ABEO | XPEV | |
|---|---|---|
Market Cap | $373.32M | $12.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $28.07 |
52-Week Low | $4.17 | $12.09 |
Enterprise Value | $228.22M | $14.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XPeng (XPEV) trades at $13.17, up 0.69% today, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with negative profitability ratios. Recent news highlights vehicle delivery growth and advancements in autonomous driving technology, but the stock faces headwinds from broader EV sector challenges.
The outlook remains cautious due to persistent losses and competitive pressures, though analyst consensus is bullish with 64.7% buy ratings. Key risks include execution on profitability, intense EV competition, and regulatory uncertainties. Revenue expansion and technology innovation present opportunities if the company can achieve sustained margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
